Editas Medicine Statistics
Total Valuation
Editas Medicine has a market cap or net worth of $465.35 million. The enterprise value is $269.21 million.
| Market Cap | 465.35M |
| Enterprise Value | 269.21M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Editas Medicine has 153.58 million shares outstanding. The number of shares has increased by 21.72% in one year.
| Current Share Class | 153.58M |
| Shares Outstanding | 153.58M |
| Shares Change (YoY) | +21.72% |
| Shares Change (QoQ) | +21.88% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 55.39% |
| Float | 115.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.90 |
| Forward PS | 26.68 |
| PB Ratio | 4.42 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.19, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.19 |
| Quick Ratio | 3.13 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20.52 |
Financial Efficiency
Return on equity (ROE) is -118.82% and return on invested capital (ROIC) is -64.75%.
| Return on Equity (ROE) | -118.82% |
| Return on Assets (ROA) | -23.29% |
| Return on Invested Capital (ROIC) | -64.75% |
| Return on Capital Employed (ROCE) | -49.41% |
| Weighted Average Cost of Capital (WACC) | 15.89% |
| Revenue Per Employee | $540,287 |
| Profits Per Employee | -$849,989 |
| Employee Count | 87 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.78% in the last 52 weeks. The beta is 2.09, so Editas Medicine's price volatility has been higher than the market average.
| Beta (5Y) | 2.09 |
| 52-Week Price Change | +9.78% |
| 50-Day Moving Average | 3.02 |
| 200-Day Moving Average | 2.62 |
| Relative Strength Index (RSI) | 50.12 |
| Average Volume (20 Days) | 2,585,966 |
Short Selling Information
The latest short interest is 24.69 million, so 16.07% of the outstanding shares have been sold short.
| Short Interest | 24.69M |
| Short Previous Month | 23.46M |
| Short % of Shares Out | 16.07% |
| Short % of Float | 21.38% |
| Short Ratio (days to cover) | 16.36 |
Income Statement
In the last 12 months, Editas Medicine had revenue of $47.01 million and -$73.95 million in losses. Loss per share was -$0.73.
| Revenue | 47.01M |
| Gross Profit | -37.95M |
| Operating Income | -83.46M |
| Pretax Income | -73.95M |
| Net Income | -73.95M |
| EBITDA | -81.04M |
| EBIT | -83.46M |
| Loss Per Share | -$0.73 |
Balance Sheet
The company has $211.65 million in cash and $15.51 million in debt, with a net cash position of $196.13 million or $1.28 per share.
| Cash & Cash Equivalents | 211.65M |
| Total Debt | 15.51M |
| Net Cash | 196.13M |
| Net Cash Per Share | $1.28 |
| Equity (Book Value) | 105.28M |
| Book Value Per Share | 0.69 |
| Working Capital | 149.63M |
Cash Flow
In the last 12 months, operating cash flow was -$119.86 million and capital expenditures -$691,000, giving a free cash flow of -$120.55 million.
| Operating Cash Flow | -119.86M |
| Capital Expenditures | -691,000 |
| Depreciation & Amortization | 2.43M |
| Net Borrowing | n/a |
| Free Cash Flow | -120.55M |
| FCF Per Share | -$0.78 |
Margins
Gross margin is -80.74%, with operating and profit margins of -177.56% and -157.32%.
| Gross Margin | -80.74% |
| Operating Margin | -177.56% |
| Pretax Margin | -157.32% |
| Profit Margin | -157.32% |
| EBITDA Margin | -172.40% |
| EBIT Margin | -177.56% |
| FCF Margin | n/a |
Dividends & Yields
Editas Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.72% |
| Shareholder Yield | -21.72% |
| Earnings Yield | -15.89% |
| FCF Yield | -25.91% |
Analyst Forecast
The average price target for Editas Medicine is $6.00, which is 98.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 98.02% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | -28.50% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Editas Medicine has an Altman Z-Score of -8.85 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.85 |
| Piotroski F-Score | 3 |